Sands Capital

Sands Capital, established in 1992, is an independent, employee-owned investment management firm based in Arlington, Virginia. It specializes in growth equity investments, focusing on both public and private markets globally. The firm's investment approach is centered around rigorous, bottom-up fundamental research to identify high-quality growth businesses across various sectors, including technology, healthcare, and consumer goods. Sands Capital offers its services to a diverse range of clients, such as pension plans, endowments, foundations, and high-net-worth individuals. It operates through two affiliates: Sands Capital Management for public market investments and Sands Capital Ventures for private market investments. The firm aims to provide long-term, active investment strategies that add value and enhance clients' wealth over time.

Ian Barnes

Managing Director

Matthew Buckley

Senior Research Associate

Brian Christiansen

Executive Managing Director, Senior Portfolio Manager and Research Analyst

Christopher Eng

Principal

Kumar Gautam

Partner

Michael J. Ginder

Partner

Michael Graninger

Managing Partner

Michael Graninger

Partner

Nicholas Graziano

Principal, Portfolio Services

David Levanson

Senior Portfolio Manager, Research Analyst and Executive Managing Director

Barron B. Martin, Jr.

Managing Partner

Annie McCormick

Director, Client Service

Mark McGovern

Venture Partner

Dana M. McNamara

Executive Managing Director and Chief Administrative Officer

Jake Merrill, CFA

Principal

Barron Martin

Research Analyst

Gene Riechers

Venture Partner

Frank M. Sands, Jr.

CEO, CIO

Marina Serenbetz

Partner

Shreya Singh

Associate

Erin Soule

Managing Director and Head of Private Markets Finance and Operations

Michael Sramek

Managing Director, Research Analyst and Senior Portfolio Manager

Christy Steele

Principal

Past deals in Infants

Vitara Biomedical

Series B in 2024
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Vitara Biomedical

Series B in 2022
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.